Harrow Secures 5-Year Strategic Agreement for Triesence and Announces Next-Generation Development

Harrow announced the execution of a 5-year strategic supply and development (SSD) agreement for Triesence (triamcinolone acetonide injectable suspension) 40 mg/mL. This preservative-free synthetic corticosteroid is FDA-approved for visualization during vitrectomy and the treatment of ocular inflammatory conditions unresponsive to topical corticosteroids.

The agreement is with the current contract manufacturing organization (CMO) responsible for producing Triesence. This move is expected to maintain the stable supply of Triesence, which had been on the FDA’s Drug Shortage List for over 5 years prior to Harrow’s acquisition of the product.

In addition to securing the long-term production of Triesence, Harrow announced its plans to develop a next-generation version of the drug. The company aims to submit a new drug application (NDA) to the FDA before the end of 2027.

“When we acquired Triesence, our first objective was to stabilize its supply and keep it off the FDA’s Drug Shortage List, where it had been for more than 5 years. By finalizing this strategic supply and development agreement, we’re ensuring the continued production of Triesence under a trusted partnership with a world-class ophthalmic pharmaceutical manufacturer," Mark L. Baum, Chairman and Chief Executive Officer of Harrow, said in a company news release.